生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BK1161 生物科技

休市中 04-17 16:00:00

6,344.387

-32.826

-0.51%

最高6,472.663	最低6,234.582	成交量2.20亿
今开6,383.529	昨收6,377.213	日振幅3.73%
总市值0.00	流通市值0.00	总股本0.00
成交额85.29亿	换手率--	流通股本0.00
市净率7.025653	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"BK1161","market":"HK","secType":"PLATE","nameCN":"生物科技","latestPrice":6344.387,"timestamp":1776413292136,"preClose":6377.213,"halted":0,"volume":219509530,"delay":0,"changeRate":-0.005147,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":-32.825684,"latestTime":"04-17 16:00:00","open":6383.5293,"high":6472.663,"low":6234.582,"amount":8529457481,"amplitude":0.037333,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776648600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1776389400000,1776398400000],[1776402000000,1776412800000]],"pbRate":7.025653,"peRate":-335.365353,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK1161/wiki","defaultTab":"wiki","newsList":[{"id":"2628021712","title":"批发毛利见底，服务重构破局：万亿医药流通靠零售“回血”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2628021712","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628021712?lang=zh_cn&edition=full","pubTime":"2026-04-17 21:55","pubTimestamp":1776434100,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者唐唯珂医药流通企业悉数交上“年度成绩单”。截至2026年4月，主要医药流通上市公司2025年年报已悉数披露。从行业龙头来看，国药控股在营收端小幅承压的同时，利润端实现逆势修复。2025年公司实现营收5751.68亿元，同比小幅下降1.60%，但归母净利润逆势增长1.50%至71.55亿元，整体经营韧性依然稳固。相比之下，华润医药展现出更为均衡的增长结构。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604173709319635.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604173709319635.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159938","BK1574","BK1515","09939","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628209911","title":"九典制药：公司正全面推进向创新药研发的战略转型","url":"https://stock-news.laohu8.com/highlight/detail?id=2628209911","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628209911?lang=zh_cn&edition=full","pubTime":"2026-04-17 20:51","pubTimestamp":1776430319,"startTime":"0","endTime":"0","summary":"谢谢九典制药回复：尊敬的投资者：您好！公司正全面推进向创新药研发的战略转型，采取“多个研发中心+多种药物形式+多种合作模式”的策略。公司在中部地区和长三角布局了双创新药研发中心，目前研发平台拥有40余名专业人员，涵盖从药物设计到临床研究的各环节，核心团队具备多个创新药临床及上市申报的成功经验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041700043115.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0239","159992","06978","300705","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628209346","title":"复宏汉霖(02696)授出合共81万份购股权及81万份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2628209346","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628209346?lang=zh_cn&edition=full","pubTime":"2026-04-17 20:43","pubTimestamp":1776429784,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖(02696)发布公告，于2026年4月17日，董事会决议根据购股权计划及受限制股份单位计划分别向142名参与者授出合共81万份购股权及81万份受限制股份单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430183.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000306685.HKD","HK0000320264.USD","HK0000320223.HKD","HK0000306701.USD","HK0000165453.HKD","02696","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628094192","title":"从长期“烧钱”到整体盈利！沙利文：创新药企进入投资价值兑现期","url":"https://stock-news.laohu8.com/highlight/detail?id=2628094192","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628094192?lang=zh_cn&edition=full","pubTime":"2026-04-17 20:37","pubTimestamp":1776429420,"startTime":"0","endTime":"0","summary":"近期，28家科创板创新药公司集中披露2025年度业绩快报。数据显示，28家公司合计实现营业收入约740亿元，同比增长近30%，创历史新高；归母净利润约16亿元，成功扭转亏损局面，实现了从长期“烧钱”到整体盈利的历史性跨越。约八成公司营收同比增长，六成公司利润端有所好转，百济神州、诺诚健华等多家企业首次实现扭亏为盈，预计将于2026年“摘U”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604173709251397.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604173709251397.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","159992","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628205561","title":"科伦博泰生物(06990)完成H股全流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2628205561","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628205561?lang=zh_cn&edition=full","pubTime":"2026-04-17 19:51","pubTimestamp":1776426712,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦博泰生物(06990)公布，合共约821.43万股内资股及非上市外资股已于2026年4月17日完成转换，且转换H股将于2026年4月20日上午九时正开始于联交所上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430127.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06990","BK1161","LU0196878994.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628820533","title":"翰思艾泰-B(03378)4月17日耗资约68.46万港元回购2.3万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2628820533","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628820533?lang=zh_cn&edition=full","pubTime":"2026-04-17 19:46","pubTimestamp":1776426375,"startTime":"0","endTime":"0","summary":"翰思艾泰-B(03378)公布，2026年4月17日耗资约68.46万港元回购2.3万股股份。","market":"us","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_27.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_27.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430121.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1535","BK1161","BK1173","03378"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628227042","title":"药捷安康-B(02617)：替恩戈替尼单药治疗晚期胆管癌患者确证性III期临床完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2628227042","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628227042?lang=zh_cn&edition=full","pubTime":"2026-04-17 18:41","pubTimestamp":1776422489,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B(02617)公布，公司核心产品替恩戈替尼(Tinengotinib, TT-00420)单药治疗晚期胆管癌患者的确证性III期临床研究，于近日完成首例患者给药。本试验为在中国开展的一项评价替恩戈替尼对比化疗用于既往经一线系统性治疗后复发或进展的、携带FGFR2融合╱重排或突变的、手术不可切除的晚期或转移性肝内胆管癌患者的疗效与安全性的随机对照、开放、多中心III期临床研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430049.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","02617","BK1161","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628168277","title":"参照药预沟通开闸，创新药医保报价打破开“盲盒”模式","url":"https://stock-news.laohu8.com/highlight/detail?id=2628168277","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628168277?lang=zh_cn&edition=full","pubTime":"2026-04-17 18:06","pubTimestamp":1776420360,"startTime":"0","endTime":"0","summary":"近日，国家医保局公示第一批参照药预沟通药品信息，共31个1类创新药，涵盖肿瘤、代谢、自身免疫等领域，涉及恒瑞、信达、亚盛、罗氏、诺华等中外头部药企。从上市情况看，23个为五年内新上市药品，1个为五年内适应症或功能主治发生重大变化的药品，另外7个则为尚未获批上市药品。在业内看来，这是为新一轮医保目录调整做铺垫。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604173709067641.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604173709067641.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1574","06978","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628277851","title":"长城基金梁福睿：关注创新药行业具备中长期价值、能真正兑现和成长的公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2628277851","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628277851?lang=zh_cn&edition=full","pubTime":"2026-04-17 17:50","pubTimestamp":1776419400,"startTime":"0","endTime":"0","summary":"近期，国内创新药及创新药产业链持续获得政策强力支持，叠加产业基本面改善与国际化突破，市场普遍看好其长期发展前景。国家药监局3月28日发布的信息显示，今年第一季度，我国创新药对外授权交易额超过600亿美元，接近2025年全年的一半。截至3月27日，今年我国已有10款创新药获批上市，其中2款为进口，8款为国产，创新药取得历史性突破。长城医药产业精选基金经理梁福睿近期就这些问题接受媒体采访，进行了专业剖析。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-04-17/doc-inhuveqy6398552.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","06978","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628274603","title":"百济神州（688235）披露提名董事及拟调整董事会专门委员会组成公告，4月17日股价下跌4.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628274603","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628274603?lang=zh_cn&edition=full","pubTime":"2026-04-17 17:17","pubTimestamp":1776417477,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘，百济神州报收于246.5元，较前一交易日下跌4.08%，最新总市值为3799.6亿元。该股当日开盘255.0元，最高255.0元，最低245.2元，成交额达11.23亿元，换手率为3.94%。百济神州有限公司于2026年4月17日发布《关于提名董事及拟调整董事会专门委员会组成的公告》。其中Baker博士、Mooney女士和Sawyers博士为新提名人，分别拟任非执行董事和独立非执行董事。四位现任独立非执行董事将不参与重选。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041700032753.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688235","LU2328871848.SGD","BK1161","LU1251922891.USD","BK1500","06160","LU0307460666.USD","LU1303224171.USD","BK1583","LU0588546209.SGD","LU1770034418.SGD","LU1719994722.HKD","BK1588","BK0239","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628276176","title":"“9号文”定价放开，创新药行情还没完","url":"https://stock-news.laohu8.com/highlight/detail?id=2628276176","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628276176?lang=zh_cn&edition=full","pubTime":"2026-04-17 16:06","pubTimestamp":1776413165,"startTime":"0","endTime":"0","summary":"创新药定价权回归市场","market":"us","thumbnail":"https://img3.gelonghui.com/c5097-aba8d577-67d2-44e6-ad65-3b7bda98b32d.jpg?guru_height=853&guru_width=1280&guru_size=168815","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/c5097-aba8d577-67d2-44e6-ad65-3b7bda98b32d.jpg?guru_height=853&guru_width=1280&guru_size=168815"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4456660","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["159992","BK1161","BK1574","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628276898","title":"4月17日昂利康（002940）涨停分析：过评提速、创新药临床驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2628276898","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628276898?lang=zh_cn&edition=full","pubTime":"2026-04-17 15:44","pubTimestamp":1776411875,"startTime":"0","endTime":"0","summary":"证券之星消息，昂利康4月17日涨停收盘，收盘价39.16元。该股于10点17分涨停，1次打开涨停，截止收盘封单资金为6392.48万元，占其流通市值0.88%。今日昂利康涨停的可能因素有：公司于2026年4月15日公告盐酸阿罗洛尔片通过一致性评价，为国内第二家获批企业；同期披露子公司创新药AL-001获CDE默示许可进入I期临床；叠加近期医药板块政策面回暖，创新药与仿制药双轮驱动逻辑受市场关注。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041700025764.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002940","BK0239","06978","BK1161","BK1574","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628275533","title":"宝济药业(02659)重组乌司他丁(BJ044)IND申请获受理，开启重组蛋白药物新纪元","url":"https://stock-news.laohu8.com/highlight/detail?id=2628275533","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628275533?lang=zh_cn&edition=full","pubTime":"2026-04-17 15:29","pubTimestamp":1776410984,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，近日，宝济药业宣布，公司自主研发的重组乌司他丁临床试验申请已正式获得国家药品监督管理局受理。数据显示，2023年中国乌司他丁市场规模约为11.6亿元。战略协同：重组技术平台的双轮驱动BJ044的IND受理，与公司另一重点产品重组人糜蛋白酶KJ101的临床进展形成了明确的战略协同。总体而言，BJ044的IND受理不仅是单一产品的进展，更代表了一种具有长期战略价值的技术方向。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429882.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IND","BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628944278","title":"AI推动创新药研发效率大幅提升，关注人工智能ETF易方达（159819）等产品配置价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2628944278","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628944278?lang=zh_cn&edition=full","pubTime":"2026-04-17 14:35","pubTimestamp":1776407757,"startTime":"0","endTime":"0","summary":"长期来看，AI与创新药的深度融合将显著降低创新药的试错成本，驱动生命科学从“经验驱动”转向“精准计算”，推动AI制药行业进入黄金时代。中证人工智能主题指数全面覆盖AI产业链上中下游核心环节，恒生港股通创新药指数成份股不含CXO公司，100%聚焦创新药企。人工智能ETF易方达、港股通创新药ETF易方达分别跟踪以上指数，管理费率均为0.15%/年，可助力投资者把握AI制药融合趋势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/SS2026041700022964.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","06978","BK1161","BK1574","159819"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628927838","title":"港股异动 | 歌礼制药-B(01672)午后涨近5% 股价逼近历史前高 GLP-1+胰淀素复方制剂启动临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2628927838","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628927838?lang=zh_cn&edition=full","pubTime":"2026-04-17 14:28","pubTimestamp":1776407328,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，歌礼制药-B午后涨近5%，高见18.68港元，逼近历史前高18.75港元。消息面上，歌礼制药近日公告，口服小分子GLP-1受体激动剂与口服小分子胰淀素受体激动剂固定剂量复方制剂ASC30_39FDC全面启动临床开发。值得关注的是，这是全球首个公开宣布的口服小分子GLP-1与口服小分子胰淀素固定剂量复方制剂，标志着歌礼在代谢疾病领域的创新布局实现关键突破。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429849.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","01672","BK4585","BK1515","VXUS","GLP","BK4590","BK4144","BK1574","BK1191","01477","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628227488","title":"破解“最凶险的乳腺癌”：为了晚期患者平均2年的生存时间延长，中国创新药做了哪些努力？| 肿瘤防治宣传周策划②","url":"https://stock-news.laohu8.com/highlight/detail?id=2628227488","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628227488?lang=zh_cn&edition=full","pubTime":"2026-04-17 13:29","pubTimestamp":1776403740,"startTime":"0","endTime":"0","summary":"青青（化名）坐在湖南省肿瘤医院的诊室里等待检查结果。此时距离她入组三阴性乳腺癌的一项III期临床试验已经一年有余，她的语气里带着一种劫后余生的庆幸：“医生说，我是疗效最好的受试者之一。”三年前，当“三阴性乳腺癌”这六个字从天而降时，她的世界曾经轰然坍塌。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604173708745959.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604173708745959.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","06978","159992","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628122206","title":"创新药赛道大幅回调，港股通创新药ETF易方达（159316）半日净申购近8000万份","url":"https://stock-news.laohu8.com/highlight/detail?id=2628122206","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628122206?lang=zh_cn&edition=full","pubTime":"2026-04-17 13:14","pubTimestamp":1776402893,"startTime":"0","endTime":"0","summary":"4月17日早盘，市场低位震荡，创新药赛道大幅回调，指数层面，恒生港股通创新药指数下跌2.4%，中证创新药产业指数下跌2.9%，港股通创新药ETF易方达半日净申购近8000万份。港股通创新药ETF易方达跟踪的恒生港股通创新药指数在编制方案中明确剔除CXO公司，100%聚焦创新药核心企业，Wind数据显示，该产品管理费率为同类中最低一档的0.15%/年，可助力投资者低成本把握创新药商业化提速机遇。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/SS2026041700022579.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","159992","BK1574","BK1161","159316"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628224855","title":"港股异动 | 君实生物(01877)再涨超3% 关注AACR大会JS207和JS212数据读出","url":"https://stock-news.laohu8.com/highlight/detail?id=2628224855","media":"智通财经","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628224855?lang=zh_cn&edition=full","pubTime":"2026-04-17 11:50","pubTimestamp":1776397803,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，君实生物(01877)再涨超3%，截至发稿，涨2.83%，报28.32港元，成交额1.08亿港元。消息面上，全球肿瘤学盛会美国癌症研究协会(AACR)2026年年会将于4月17日至22日在美国圣地亚哥会议中心举行。太平洋证券指出，君实生物JS207(PD-1/VEGF)于2026 AACR大会上披露1LCRC(联合化疗)、1LHCC(联合CTLA4单抗)临床数据，有望年内进入关键注册临床；JS212(EGFR/HER3ADC)于AACR上披露早期数据，计划年底启动关键注册临床。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429815.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","688180","BK1583","BK4585","BK1161","BK4588","BK0239","VXUS","01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628282162","title":"宝莫股份：目前公司产品暂未应用于医药领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2628282162","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628282162?lang=zh_cn&edition=full","pubTime":"2026-04-17 08:39","pubTimestamp":1776386347,"startTime":"0","endTime":"0","summary":"证券之星消息，宝莫股份(002476)04月16日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，请问公司产品可以衍生用于医药领域？宝莫股份回复：尊敬的投资者您好！公司主要产品涵盖聚丙烯酰胺、稠油降粘剂、表面活性剂等，相关产品主要应用于油气开发领域的三次采油作业、废水处理等场景，目前公司产品暂未应用于医药领域。感谢您对公司的关注与支持！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041700009958.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK1515","BK1161","159938","09939","BK1574","002476","BK0229","BK0004","BK0144"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627113702","title":"下一个“减肥药”？降脂针从 2000 元变 300 元，药企疯狂内卷会否重蹈覆辙","url":"https://stock-news.laohu8.com/highlight/detail?id=2627113702","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627113702?lang=zh_cn&edition=full","pubTime":"2026-04-16 21:49","pubTimestamp":1776347370,"startTime":"0","endTime":"0","summary":"单针从9988元骤降至2790元，近2000元的降脂针“腰斩再腰斩”至300元级！长效降脂针医保落地至今早已满三个月，这场颠覆性的价格变革，让曾经的“天价救命针”变身“亲民药”，诺华、安进、信达生物等中外药企争相入局，咨询量、备货量迎来爆发式激增，千亿美元降脂赛道瞬间沸腾，一场没有硝烟的市场洗牌正激烈上演。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604163707833565.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604163707833565.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2097828631.EUR","LU0455707207.USD","LU1969619763.USD","01801","LU2097828474.EUR","LU2328871848.SGD","LU2097828805.USD","LU2242644610.SGD","LU0502904849.HKD","BK1583","BK1589","HK0000165453.HKD","LU2097828714.EUR","LU2488822045.USD","LU2097828557.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":0.0103},{"period":"1month","weight":0.0052},{"period":"3month","weight":-0.0255},{"period":"6month","weight":0.0362},{"period":"1year","weight":0.2227},{"period":"ytd","weight":0.0207}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"name":"BK1161","nameEN":"BK1161"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物科技(BK1161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物科技,BK1161,生物科技股票,生物科技股票老虎,生物科技股票老虎国际,生物科技行情,生物科技股票行情,生物科技股价,生物科技股市,生物科技股票价格,生物科技股票交易,生物科技股票购买,生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物科技(BK1161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}